Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 1, 2010, Pages 19-33

  Yarows, Steven A ^a  

^a Chelsea Internal Medicine   (United States)

Author keywords

aliskiren; angiotensin receptor blocker; blood pressure; direct renin inhibitor; hypertension; plasma renin activity; renin angiotensin aldosterone system; single pill combination; valsartan

Indexed keywords

ALISKIREN; AMLODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN; AMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; FUMARIC ACID DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

AREA UNDER THE CURVE; BACKACHE; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; POTASSIUM BLOOD LEVEL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FUMARATES; HUMANS; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE;

EID: 77949528492     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.143     Document Type: Review

References (97)

1. Weir MR, Dzau VJ. The renin- angiotensin-aldosterone system: a specific target for hypertension management. Am. J. Hypertens. 12, S205-S213 (1999).
2. Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J. Am. Soc. Nephrol. 13(Suppl. 3), S173-S178 (2002).
3. Turnbull F. Effects of different blood- pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527-1535 (2003).
4. Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev. Cardiovasc. Med. 7, 45-54 (2006).
5. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759-766 (2003). (Pubitemid 37093915)
6. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, S1-S266 (2002).
9. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. 24, 243-256 (2006).
10. Bair TL, May HT, Prescott MF et al. Association between baseline plasma renin activity and risk of cardiovascular events in coronary artery disease patients. J. Clin. Hypertens. 11(Suppl. A), A88 (2009) (Abstract: P-176).
11. Vergaro G, Fontana M, Poletti R et al. Plasma renin activity is an independent prognostic factor in chronic heart failure. Eur. Heart J. 29(Suppl. 1), 393 (2008).
12. Latini R, Masson S, Anand I et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur. Heart J. 25, 292-299 (2004).
13. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 67, 1767-1792 (2007).
14. Burnier M, Brown RE, Ong SH, Keskinaslan A, Khan ZM. Issues in blood pressure control and the potential role of single-pill combination therapies. Int. J. Clin. Pract. 63, 790-798 (2009).
15. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120, 713-719 (2007).
16. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54, 299-311 (1997). (Pubitemid 27361837)
17. Mistry NB, Westheim AS, Kjeldsen SE. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin. Pharmacother. 7, 575-581 (2006).
18. Ripley TL. Valsartan in chronic heart failure. Ann. Pharmacother. 39, 460-469 (2005).
19. Ruilope LM. Valsartan and the kidney: review of preclinical and clinical data. Adv. Ther. 18, 57-66 (2001).
20. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022-2031 (2004).
21. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded end point morbidity- mortality study. Lancet 369, 1431-1439 (2007).
22. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
23. Vaidyanathan S, Jarugula V, Dieterich H-A, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet. 47, 515-531 (2008).
24. Waldmeier F, Glaenzel U, Wirz B et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab. Dispos. 35, 1418-1428 (2007).
25. Vaidyanathan S, Valencia J, Kemp C et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract. 60, 1343-1356 (2006).
26. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221-229 (2007).
27. Geiger H, Barranco E, Gorostidi M et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J. Clin. Hypertens. 11, 324-332 (2009).
28. Loriga G, Vidili G, Ruggenenti P, Faedda R, Sanna M, Satta AE. Renal hemodynamics and renoprotection. Nephron Clin. Pract. 110, C213-C219 (2008).
29. Verma A, Juszczynska K, Uno H et al. Neurohumoral effects of a new oral direct renin inhibitor in patients with left ventricular hypertrophy: the aliskiren in left ventricular hypertrophy (ALLAY) trial. J. Hypertens. 27, S314 (2009).
30. McMurray J, Pitt B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation 1, 17-24 (2008).
31. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
32. Danser AH, van Kesteren CA, Bax WA et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 96, 220-226 (1997).
33. Chiarelli F, Pomilio M, De Luca FA, Vecchiet J, Verrotti A. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr. Nephrol. 16, 116-120 (2001).
34. Danser AH, van den Dorpel MA, Deinum J et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. 68, 160-167 (1989).
35. Deinum J, Ronn B, Mathiesen E, Derkx FH, Hop WC, Schalekamp MA. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 42, 1006-1010 (1999).
36. Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J. Clin. Invest. 114, 1128-1135 (2004).
37. Ichihara A, Kaneshiro Y, Takemitsu T et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47, 894-900 (2006).
38. Ichihara A, Suzuki F, Nakagawa T et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor- deficient mice. J. Am. Soc. Nephrol. 17, 1950-1961 (2006).
39. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro) renin signaling. J. Am. Soc. Nephrol. 19, 743-748 (2008).
40. Feldt S, Batenburg WW, Mazak I et al. Prorenin and renin-induced ERK 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51, 682 (2008).
41. Melnyk RA, Tam J, Boie Y, Kennedy BP, Percival MD. Renin and prorenin activate pathways implicated in organ damage in human mesangial cells independent of angiotensin ii production. Am. J. Nephrol. 30, 232-243 (2009).
42. Nguyen G. The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr. Opin. Nephrol. Hypertens. 16, 129-133 (2007).
43. Batenburg WW, de Bruin RJ, van Gool JM et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 28(6), 1151-1157 (2008).
44. Sakoda M, Ichihara A, Mito A et al. Effects of renin inhibition on activated prorenin in human podocytes. J. Hypertens. 26, S199 (2008).
45. Nguyen G, Contrepas A, Mueller DN et al. Effect of the direct renin inhibitor aliskiren on (pro)renin receptor and profibrotic gene expression in kidneys of diabetic TG(mRen-2)27 rats. J. Am. Soc. Nephrol. 18 (2007).
46. Feldman DL, Jin L, Xuan H et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mREN-2)27 rats. Hypertension 52, 130-136 (2008).
47. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose- dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens. Res. 29, 997-1005 (2006).
48. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111, 1012-1018 (2005).
49. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol. 49, 1157-1163 (2007).
50. Schmieder RE, Philipp T, Guerediaga J et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 119, 417-425 (2009).
51. Andersen K, Weinberger MH, Egan B et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J. Hypertens. 26, 589-599 (2008).
52. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42, 1137-1143 (2003).
53. Drummond W, Munger MA, Essop MR, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J. Clin. Hypertens. 9, 742-750 (2007).
54. Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 25, 217-226 (2007).
55. Uresin Y, Taylor AA, Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst. 8, 190-198 (2007).
56. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J. Hum. Hypertens. DOI: doi:10.1038/jhh.2009.38 (2009) (Epub ahead of print).
57. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336, 1114-1117 (2008).
58. Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am. J. Hypertens. 20, 11-20
59. Chrysant SG, Murray AV, Hoppe UC et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr. Med. Res. Opin. 24, 1039-1047 (2008).
60. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45, 880-886 (2005).
61. White WB, Lewin A, Singh A, Koval S, Schlesinger AC, DeFeo H. Pivotal clinical trial results for combining the angiotensin receptor blocker telmisartan with the angiotensin converting enzyme inhibitor ramipril. J. Clin. Hypertens. 10(5), A127
62. Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv. Ther. 1288-1302 (2008).
63. Yarows SA, Oparil S, Patel S, Arora V, Zhang J. Aliskiren in combination with valsartan provides additional blood pressure-lowering effects compared with either agent alone in elderly and younger patients with hypertension. J. Hypertens. S19-S20 (2008).
64. Yarows SA, Oparil S, Patel S, Arora V, Zhang J. Aliskiren in combination with valsartan lowers blood pressure more effectively than either agent alone in patients with hypertension, regardless of metabolic status: a post-hoc analysis of an 8-week double-blind study. Diabetologia 51, S493 (2008).
65. Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N. Engl. J. Med. 357, 789-796 (2007).
66. Arcucci O, de Simone G, Izzo R et al. Association of suboptimal blood pressure control with body size and metabolic abnormalities. J. Hypertens. 25, 2296-2300 (2007).
67. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J. Am. Geriatr. Soc. 55, 1056-1065 (2007).
68. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am. J. Cardiol. 75, 793-795 (1995).
69. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J. Hypertens. Suppl. 19, S41-S48 (2001).
70. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am. J. Cardiol. 92, 38-42 (2003).
71. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
72. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin- angiotensin blockade in hypertensive patients. Hypertension 40, 117-123 (2002).
73. Izzo JL Jr, Weinberg MS, Hainer JW, Kerkering J, Tou CK. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J. Clin. Hypertens. 6, 485-493 (2004).
74. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
75. Solomon SD, Appelbaum E, Manning WJ et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients With hypertension and left ventricular hypertrophy. Circulation 119, 530-537 (2009).
76. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J. Renin Angiotensin Aldosterone Syst. 10, 65-76 (2009).
77. Parving HH, Lehnert H, Brochner- Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. 345, 870-878 (2001).
78. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End point Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002). (Pubitemid 34286536)
79. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292, 2350-2356 (2004).
80. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J. Am. Coll. Cardiol. 43, 2116-2123 (2004).
81. Mizuta Y, Kai H, Mizoguchi M et al. Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment. Hypertens. Res. 31, 1835-1842 (2008).
82. Suzuki K, Kato K, Soda S, Kamimura T, Aizawa Y. The effect of valsartan on regression of left ventricular hypertrophy in Type 2 diabetic patients. Diabetes Obes. Metab. 6, 195-199 (2004).
83. James SK, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV substudy. Circulation 108, 275-281 (2003)
84. de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345, 1014-1021 (2001).
85. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351, 2058-2068 (2004).
86. Fox KM. Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients with Stable Coronary Artery Disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782-788 (2003).
87. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal End points (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. DOI: 10.1093/ ndt/gfn721 (2009) (Epub ahead of print).
88. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893-1906 (2003).
89. Taylor A, Anderson DR, Arora V, Satlin A, Prescott MF. Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertension. J. Am. Coll. Cardiol. 49, 370A; P1014-P1170 (2007).
90. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet. Med. 24, 486-493 (2007).
91. Jayawant S, Fulcher N, Ramamurthy P, Moyneur E, Ong S, Duh M. Cost trend associated with cardiovascular (CV) events in patients (Pts) with hypertension (Htn) in US managed care settings. J. Clin. Hypertens. 11(Suppl. A), A57-A58 (2009).
92. Palmer JL, Munk VC, Kotchie RW et al. Cost-effectiveness of aliskiren as add on to losartan and optimal antihypertensive therapy in patients with Type 2 diabetes, hypertension and nephropathy in the UK setting. Am. J. Kidney Dis. 51, A76 (2008).
93. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49, 69-75 (2007).
94. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
95. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
96. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Eng. J. Med. 341, 709-717 (1999).
97. NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).